University Cardiology Unit, Cardiothoracic Department, Policlinic University Hospital, 70124, Bari, Italy.
Clinic Pathology Unit, Policlinic University Hospital, 70124, Bari, Italy.
Biomark Med. 2019 Jun;13(9):707-713. doi: 10.2217/bmm-2018-0349. Epub 2019 Jun 3.
The aim of the study was to evaluate the association between Gal-3 serum levels and the progression of renal dysfunction in chronic heart failure outpatients. This prospective study of 260 chronic heart failure patients showed that Gal-3 was associated with 1-year worsening of renal function both in univariate (odds ratio: 1.12; 95% CI: 1.06-1.18; p < 0.001) and in forward stepwise multivariate (odds ratio: 1.09; 95% CI: 1.03-1.15; p = 0.004) logistic regression analyses. Moreover, high Gal-3 levels at baseline were associated with a progressive decline in the estimated glomerular filtration rate. Gal-3 is a biomarker associated with the progression of renal function decline thus further supporting its possible usefulness in predicting cardiorenal syndrome progression.
本研究旨在评估 Gal-3 血清水平与慢性心力衰竭门诊患者肾功能恶化之间的关系。这项对 260 例慢性心力衰竭患者的前瞻性研究表明，Gal-3 与肾功能恶化 1 年相关，无论是在单因素（比值比：1.12；95%可信区间：1.06-1.18；p<0.001）还是向前逐步多因素（比值比：1.09；95%可信区间：1.03-1.15；p=0.004）逻辑回归分析中均如此。此外，基线时高 Gal-3 水平与估计肾小球滤过率的进行性下降相关。Gal-3 是与肾功能下降进展相关的生物标志物，因此进一步支持其在预测心肾综合征进展方面的可能有用性。
